Compare AGX & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGX | KYMR |
|---|---|---|
| Founded | 1961 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 10.6B |
| IPO Year | 1995 | 2020 |
| Metric | AGX | KYMR |
|---|---|---|
| Price | $468.98 | $121.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 26 |
| Target Price | ★ $409.50 | $107.72 |
| AVG Volume (30 Days) | 271.6K | ★ 637.1K |
| Earning Date | 03-26-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.32% | N/A |
| EPS Growth | ★ 58.37 | N/A |
| EPS | ★ 3.24 | N/A |
| Revenue | ★ $944,606,000.00 | $39,211,000.00 |
| Revenue This Year | $33.81 | $10.61 |
| Revenue Next Year | $20.97 | $8.17 |
| P/E Ratio | $154.82 | ★ N/A |
| Revenue Growth | ★ 8.06 | N/A |
| 52 Week Low | $197.00 | $39.84 |
| 52 Week High | $805.75 | $130.05 |
| Indicator | AGX | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 31.69 | 60.54 |
| Support Level | $401.98 | $76.40 |
| Resistance Level | $492.70 | $120.37 |
| Average True Range (ATR) | 29.14 | 4.60 |
| MACD | -7.30 | 0.88 |
| Stochastic Oscillator | 6.20 | 69.30 |
Argan Inc is a United States-based construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC, and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Teledata, out of which Power Services derives the majority of revenue.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.